Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study

European Journal of Epidemiology

Volumn 30, Issue 2, 2015, Pages 131-141

  di Giuseppe, Romina ^a,g   Kühn, Tilmann ^b   Hirche, Frank ^c   Buijsse, Brian ^a   Dierkes, Jutta ^d   Fritsche, Andreas ^e   Kaaks, Rudolf ^b   Boeing, Heiner ^a   Stangl, Gabriele I ^c   Weikert, Cornelia ^a,f,g  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF BERGEN   (Norway)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Directed acyclic graph; Hemorrhagic stroke; Ischemic stroke; Myocardial infarction; Phosphaturic hormone

Indexed keywords

CALCIFEDIOL; CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; AGE; ARTICLE; BODY MASS; BRAIN HEMORRHAGE; CALCIUM INTAKE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEART INFARCTION; HORMONE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY, CAPACITY AND PERFORMANCE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMOKING; VITAMIN INTAKE; WAIST CIRCUMFERENCE; AGE DISTRIBUTION; AGED; BLOOD; CARDIOVASCULAR DISEASES; GERMANY; HEALTH SURVEY; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTOR; SEX RATIO; STROKE; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FIBROBLAST GROWTH FACTORS; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; STROKE;

EID: 84925539532     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-014-9982-4     Document Type: Article

References (47)

1. Quarles LD. The bone and beyond: ‘Dem bones’ are made for more than walking. Nat Med. 2011;17(4):428–30. doi:10.1038/nm0411-428.
2. Hori M, Shimizu Y, Fukumoto S. Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology. 2011;152(1):4–10. doi:10.1210/en.2010-0800.
3. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195(1):125–31.
4. Kovesdy CP, Quarles LD. Fibroblast growth factor-23: what we know, what we don’t know, and what we need to know. Nephrol Dial Transplant. 2013. doi:10.1093/ndt/gft065.
5. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study. Ann Intern Med. 2010;152(10):640–8. doi:10.1059/0003-4819-152-10-201005180-00004.
6. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011;161(5):956–62. doi:10.1016/j.ahj.2011.02.012.
7. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (cardiovascular health study). J Am Coll Cardiol. 2012;60(3):200–7. doi:10.1016/j.jacc.2012.03.040.
8. Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol CJASN. 2013;8(5):781–6. doi:10.2215/CJN.09570912.
9. Udell JA, O’Donnell T, Morrow D, Jarolim P, Omland T, Sloan S, et al. Association of fibroblast growth factor (FGF)-23 levels with risk of cardiovascular events in patients with stable coronary artery disease. J Am Coll Cardiol. 2012;59(13):E1480. doi:10.1016/S0735-1097(12)61481-8.
10. di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-HydroxyvitaminD3 and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab. 2013. doi:10.1210/jc.2013-2963.
11. Wright CB, Dong C, Stark M, Silverberg S, Rundek T, Elkind MS, et al. Plasma FGF23 and the risk of stroke: the Northern manhattan study (NOMAS). Neurology. 2014. doi:10.1212/WNL.0000000000000410.
12. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014. doi:10.1002/emmm.201303716.
13. Heine GH, Seiler S, Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrology, dialysis, transplantation: official publication of the European dialysis and transplant association—European renal association. 2012;27(8):3072–81. doi:10.1093/ndt/gfs259.
14. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113–24. doi:10.1079/PHN2002394.
15. Riboli E, Kaaks R. The EPIC project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol. 1997;26(Suppl 1):S6–14.
16. Boeing H, Wahrendorf J, Becker N. EPIC-Germany—a source for studies into diet and risk of chronic diseases. European investigation into cancer and nutrition. Ann Nutr Metab. 1999;43(4):195–204.
17. Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European investigation into cancer and nutrition. Ann Nutr Metab. 1999;43(4):205–15.
18. Bergmann MM, Bussas U, Boeing H. Follow-up procedures in EPIC-Germany—data quality aspects. European prospective investigation into cancer and nutrition. Ann Nutr Metab. 1999;43(4):225–34.
19. Prentice LR. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73:1–11.
20. InterAct C, Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, et al. Design and cohort description of the interact project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC study. Diabetologia. 2011;54(9):2272–82. doi:10.1007/s00125-011-2182-9.
21. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118(24):2555–62. doi:10.1161/CIRCULATIONAHA.108.814418.
22. Weikert C, Berger K, Heidemann C, Bergmann MM, Hoffmann K, Klipstein-Grobusch K, et al. Joint effects of risk factors for stroke and transient ischemic attack in a German population: the EPIC potsdam study. J Neurol. 2007;254(3):315–21. doi:10.1007/s00415-006-0358-x.
23. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90(1):583–612.
24. Kuhn T, Kaaks R, Teucher B, Hirche F, Dierkes J, Weikert C, et al. Plasma 25-hydroxyvitamin D and its genetic determinants in relation to incident myocardial infarction and stroke in the European prospective investigation into cancer and nutrition (EPIC)-Germany study. PLoS one. 2013;8(7):e69080. doi:10.1371/journal.pone.0069080.
25. Danesh J, Saracci R, Berglund G, Feskens E, Overvad K, Panico S, et al. EPIC-Heart: the cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries. Eur J Epidemiol. 2007;22(2):129–41. doi:10.1007/s10654-006-9096-8.
26. di Giuseppe R, Hirche F, Montonen J, Buijsse B, Dierkes J, Stangl GI, et al. Reliability of plasma fibroblast growth factor 23 as risk biomarker in epidemiological studies measured over a four-month period. Ann Clin Biochem. 2012;49(Pt 6):542–5. doi:10.1258/acb.2012.011273.
27. Buijsse B, Boeing H, Hirche F, Weikert C, Schulze MB, Gottschald M, et al. Plasma 25-hydroxyvitamin D and its genetic determinants in relation to incident type 2 diabetes: a prospective case-cohort study. Eur J Epidemiol. 2013;28(9):743–52. doi:10.1007/s10654-013-9844-5.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
29. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European prospective investigation into cancer and nutrition (EPIC) study. Public health Nutr. 2003;6(4):407–13. doi:10.1079/PHN2002439.
30. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology. 2011;22(5):745. doi:10.1097/EDE.0b013e318225c2be.
31. Hopke PK, Liu C, Rubin DB. Multiple imputation for multivariate data with missing and below-threshold measurements: time-series concentrations of pollutants in the Arctic. Biometrics. 2001;57(1):22–33.
32. Panwar B, Jenny N, Howard V, Wadley V, Muntner P, Judd S, et al. Abstract T P134: fibroblast growth factor 23 and risk of incident stroke in the regards study. Stroke. 2014;45(Suppl 1):ATP134.
33. Lutsey PL, Selvin E, Misialek JR, Michos ED, Rebholz CM, Gottesman RF, et al. Abstract P222: serum fibroblast growth factor-23 and risk of incident stroke: the atherosclerosis risk in communities study (ARIC). Circulation. 2014;129(Suppl 1):AP222.
34. Tuñón J, Cristóbal C, Tarin N, Gonzalez-Parra E, Aceña Á, Gonzalez-Casaus ML, et al. Fibroblast growth factor 23 and low 25 OH Vitamin D plasma levels are independent predictors of cardiovascular events in patients with chronic coronary artery disease. J Am Coll Cardiol. 2013. doi:10.1016/S0735-1097(13)61451-5.
35. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol JASN. 2010;21(9):1427–35. doi:10.1681/ASN.2009121293.
36. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205(2):385–90.
37. Zoccali C, Yilmaz MI, Mallamaci F. FGF23: a mature renal and cardiovascular risk factor? Blood Purif. 2013;36(1):52–7. doi:10.1159/000351001.
38. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol JASN. 2011;22(9):1603–9. doi:10.1681/ASN.2010121251.
39. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273–92. doi:10.1111/j.1476-5381.2010.00750.x.
40. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–52. doi:10.1161/CIRCULATIONAHA.108.844506.
41. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408. doi:10.1172/JCI46122.
42. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207(2):546–51.
43. Bots ML, Nikitin Y, Salonen JT, Elwood PC, Malyutina S, de Freire Concalves A, et al. Left ventricular hypertrophy and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health. 2002;56(Suppl 1):i8–13.
44. Bauml MA, Underwood DA. Left ventricular hypertrophy: an overlooked cardiovascular risk factor. Clevel Clin J Med. 2010;77(6):381–7. doi:10.3949/ccjm.77a.09158.
45. Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab. 2012;97(4):E575–83. doi:10.1210/jc.2011-2836.
46. Imazu M, Takahama H, Asanuma H, Funada A, Ohara T, Hasegawa T, et al. Clinical significance of serum fibroblast growth factor 23 as a surrogate marker of the cardiorenal hemodynamic state in patients with heart failure. Eur Heart J. 2013;34(suppl 1):P4242.
47. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37–48.